The REaCT low-risk HER2 study (NCT03705429) compared two commonly used systemic therapy regimens for early-stage HER2-positive breast cancer to establish the optimal option in terms of toxicity profile, cost-effectiveness and quality of life measured with FACT-Taxane and -Fatigue scores [48]. The gene discussed is ERBB2; the disease is breast cancer.